SLXP to acquire SNTS# Stock
S*t
1 楼
RALEIGH, N.C. & SAN DIEGO--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (
NASDAQ:SLXP) and Santarus, Inc. (NASDAQ:SNTS) today announced that the
companies have entered into a definitive merger agreement under which Salix
will acquire all of the outstanding common stock of Santarus for $32.00 per
share in cash (without interest). The all-cash transaction values Santarus
at approximately $2.6 billion. The $32.00 per share price represents an
approximately 36% premium over Santarus’ November 6, 2013 closing price of
$23.53 per share and an approximately 39% premium over Santarus’ average
closing stock price for the prior 30-trading day period. The proposed
transaction has been unanimously approved by the Boards of Directors of
Salix and Santarus. The companies expect to close the transaction in the
first quarter of 2014.
NASDAQ:SLXP) and Santarus, Inc. (NASDAQ:SNTS) today announced that the
companies have entered into a definitive merger agreement under which Salix
will acquire all of the outstanding common stock of Santarus for $32.00 per
share in cash (without interest). The all-cash transaction values Santarus
at approximately $2.6 billion. The $32.00 per share price represents an
approximately 36% premium over Santarus’ November 6, 2013 closing price of
$23.53 per share and an approximately 39% premium over Santarus’ average
closing stock price for the prior 30-trading day period. The proposed
transaction has been unanimously approved by the Boards of Directors of
Salix and Santarus. The companies expect to close the transaction in the
first quarter of 2014.